NEW YORK (360Dx) – Ceres Nanosciences said on Thursday it has closed on an additional $5.5 million in Series A funding, bringing the round's total to $8.5 million.

The company said it will use the funds to further development of its Nanotrap Lyme Antigen Test System for detecting Lyme disease, as well as development of new applications for its Nanotrap technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.